ACTG 175 was a randomized clinical trial to compare monotherapy with zidovudine or didanosine with combination therapy with zidovudine and didanosine or zidovudine and zalcitabine in adults infected with the human immunodeficiency virus type I whose CD4 T cell counts were between 200 and 500 per cubic millimeter.
data(ACTG175)A data frame with 2139 observations on the following 27 variables:
pidnumpatien ID number
ageage in years at baseline
wtkgweight in kg at baseline
hemohemophilia (0=no, 1=yes)
homohomosexual activity (0=no, 1=yes)
drugshistory of intravenous drug use (0=no, 1=yes)
karnofKarnofsky score (on a scale of 0-100)
opriornon-zidovudine antiretroviral therapy prior to initiation of study treatment (0=no, 1=yes)
z30zidovudine use in the 30 days prior to treatment initiation (0=no, 1=yes)
zpriorzidovudine use prior to treatment initiation (0=no, 1=yes)
preantinumber of days of previously received antiretroviral therapy
racerace (0=white, 1=non-white)
gendergender (0=female, 1=male)
str2antiretroviral history (0=naive, 1=experienced)
stratantiretroviral history stratification (1='antiretroviral naive', 2='> 1 but <= 52 weeks of prior antiretroviral therapy', 3='> 52 weeks')
symptomsymptomatic indicator (0=asymptomatic, 1=symptomatic)
treattreatment indicator (0=zidovudine only, 1=other therapies)
offtrtindicator of off-treatment before 96+/-5 weeks (0=no,1=yes)
cd40CD4 T cell count at baseline
cd420CD4 T cell count at 20+/-5 weeks
cd496CD4 T cell count at 96+/-5 weeks (=NA if missing)
rmissing CD4 T cell count at 96+/-5 weeks (0=missing, 1=observed)
cd80CD8 T cell count at baseline
cd820CD8 T cell count at 20+/-5 weeks
censindicator of observing the event in days
daysnumber of days until the first occurrence of: (i) a decline in CD4 T cell count of at least 50 (ii) an event indicating progression to AIDS, or (iii) death.
armstreatment arm (0=zidovudine, 1=zidovudine and didanosine, 2=zidovudine and zalcitabine, 3=didanosine).
The variable days contains right-censored time-to-event
observations. The data set includes the following post-randomization
covariates: CD4 and CD8 T cell count at 20+/-5 weeks and the indicator
of whether or not the patient was taken off-treatment before
96+/-5 weeks.
Hammer SM, et al. (1996) A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. New England Journal of Medicine 335, 1081-1090.